RAPT Therapeutics (RAPT) News Today → Digitizing the $11T commodities sector with one tiny stock (From Resource Stock Digest) (Ad) Free RAPT Stock Alerts $4.00 -0.04 (-0.99%) (As of 05:19 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 8:06 AM | seekingalpha.comRAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric OpportunityMay 16, 2024 | americanbankingnews.comRAPT Therapeutics (NASDAQ:RAPT) Rating Reiterated by Wolfe ResearchMay 14, 2024 | msn.comWolfe downgrades RAPT, but still sees "immense" upside potentialMay 14, 2024 | marketbeat.comWolfe Research Reaffirms "Peer Perform" Rating for RAPT Therapeutics (NASDAQ:RAPT)Wolfe Research reiterated a "peer perform" rating on shares of RAPT Therapeutics in a research report on Tuesday.May 14, 2024 | americanbankingnews.comRAPT Therapeutics (NASDAQ:RAPT) Downgraded by Guggenheim to "Neutral"May 14, 2024 | americanbankingnews.comRAPT Therapeutics (NASDAQ:RAPT) Downgraded to Equal Weight at BarclaysMay 12, 2024 | finance.yahoo.comHere's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn SituationMay 11, 2024 | msn.comRAPT terminates Phase II trials for lead candidate following clinical holdMay 11, 2024 | msn.comBarclays Downgrades RAPT Therapeutics (RAPT)May 10, 2024 | markets.businessinsider.comMaintaining Hold Rating on RAPT Therapeutics Amid Clinical Uncertainties and Financial OutlookMay 10, 2024 | msn.comRAPT falls for second day as Guggenheim, Barclays downgrade stockMay 10, 2024 | finance.yahoo.comRAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial OverviewMay 10, 2024 | marketbeat.comTimesSquare Capital Management LLC Invests $12.53 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)TimesSquare Capital Management LLC purchased a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 504,340 shares of the company's stoMay 10, 2024 | marketbeat.comGuggenheim Lowers RAPT Therapeutics (NASDAQ:RAPT) to NeutralGuggenheim cut RAPT Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday.May 9, 2024 | morningstar.comRAPT Therapeutics Shares Hit 52-Week Low After Trials ClosedMay 9, 2024 | finance.yahoo.comRAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon TrialsMay 9, 2024 | finance.yahoo.comWhat's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?May 9, 2024 | investorplace.comRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024May 9, 2024 | marketbeat.comTrading was temporarily halted for "RAPT" at 10:05 AM with a stated reason of "LULD pause."May 9, 2024 | globenewswire.comRAPT Therapeutics Reports First Quarter 2024 Financial ResultsApril 12, 2024 | markets.businessinsider.comHold Rating on RAPT Therapeutics Amid Promising Data and Regulatory UncertaintiesApril 11, 2024 | investing.comRAPT reports positive phase 2 cancer trial resultsApril 10, 2024 | markets.businessinsider.comMaintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory UncertaintyApril 10, 2024 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Earns Neutral Rating from HC WainwrightHC Wainwright restated a "neutral" rating on shares of RAPT Therapeutics in a report on Wednesday.April 9, 2024 | globenewswire.comRAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsApril 9, 2024 | investorplace.com3 Biotech Stocks to Dump Before They Go to ZeroApril 4, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Moderate Buy" from AnalystsRAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve brokerages that are presently covering the company, Marketbeat reports. Six analysts have rated the stock with a hold recommendation and six have issued a buy recommendApril 1, 2024 | marketbeat.comShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 32.5%RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 3,300,000 shares, a growth of 32.5% from the February 29th total of 2,490,000 shares. Based on an average daily trading volume, of 1,210,000 shares, the days-to-cover ratio is presently 2.7 days.March 27, 2024 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Price Target Cut to $13.00JPMorgan Chase & Co. reduced their price target on shares of RAPT Therapeutics from $15.00 to $13.00 and set a "neutral" rating on the stock in a research report on Wednesday.March 16, 2024 | finance.yahoo.comRAPT Apr 2024 10.000 putMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTMarch 11, 2024 | markets.businessinsider.comHold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial ConcernsMarch 8, 2024 | finance.yahoo.comRAPT Oct 2024 5.000 callMarch 7, 2024 | investorplace.comRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023March 7, 2024 | globenewswire.comRAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 5, 2024 | globenewswire.comRAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTMarch 1, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Bought by Braidwell LPBraidwell LP grew its holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 10.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,082,512 shares of the company's stock after acquiring an addiFebruary 29, 2024 | marketbeat.comFmr LLC Grows Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)Fmr LLC increased its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 7.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,499,293 shares of the company's stock after aFebruary 26, 2024 | businesswire.comRAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsFebruary 23, 2024 | finance.yahoo.comRAPT May 2024 17.500 putFebruary 22, 2024 | msn.comUBS Downgrades RAPT Therapeutics (RAPT)February 22, 2024 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Downgraded by UBS Group to NeutralUBS Group cut shares of RAPT Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $61.00 to $10.00 in a report on Thursday.February 21, 2024 | msn.comHC Wainwright & Co. Downgrades RAPT Therapeutics (RAPT)February 21, 2024 | msn.comLeerink Partners Downgrades RAPT Therapeutics (RAPT)February 21, 2024 | realmoney.thestreet.comRapt Therapeutics just downgraded at Leerink, here's whyFebruary 21, 2024 | msn.comJ.P. Morgan cuts RAPT to neutral, recommends against buying dipFebruary 21, 2024 | msn.comH.C. Wainwright cuts RAPT to neutral, cites delays due to clinical holdFebruary 21, 2024 | markets.businessinsider.comWhat's Going On With RAPT Therapeutics Stock On Wednesday?February 21, 2024 | marketbeat.comBarclays Lowers RAPT Therapeutics (NASDAQ:RAPT) Price Target to $13.00Barclays reduced their target price on RAPT Therapeutics from $35.00 to $13.00 and set an "overweight" rating for the company in a report on Wednesday. Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Everybody laughed when he recommended Netflix (Ad)"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. RAPT Media Mentions By Week RAPT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAPT News Sentiment▼0.130.42▲Average Medical News Sentiment RAPT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAPT Articles This Week▼72▲RAPT Articles Average Week Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Sagimet Biosciences News Today Regulus Therapeutics News Today Seres Therapeutics News Today Syros Pharmaceuticals News Today Cartesian Therapeutics News Today InterCure News Today Renovaro News Today PDS Biotechnology News Today I-Mab News Today Skye Bioscience News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RAPT) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWarren Buffett's "mystery stock"Stansberry ResearchDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
